Monsanto Company (NYSE:MON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, Monsanto Company (the "Company") is party to a merger agreement providing for the acquisition of the Company by Bayer Aktiengesellschaft ("Bayer") on the terms and conditions contained therein. The completion of the merger remains subject to satisfaction of certain closing conditions, including receipt of required regulatory approvals.
On May 7, 2018, the Company's Chairman and Chief Executive Officer announced that he will be departing the Company at the closing of the merger. In addition, on May 7, 2018, the Company's Senior Vice President and Chief Financial Officer, the Company's Executive Vice President and Chief Technology Officer and the Company's Executive Vice President, Secretary and General Counsel announced that they will be departing the Company shortly after the closing of the merger. Current executives of the Company who will transition to become members of the Crop Science Executive Leadership Team at Bayer once the merger is closed include the Company's President and Chief Operating Officer.
All of the foregoing officers are expected to continue in their current roles through the completion of the merger.
Item 7.01. Regulation FD Disclosure
On May 7, 2018, the Company issued a press release regarding certain of the matters described in Item 5.02, which press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.